10-K: Odyssey Health 10-K: Going Concern Doubts Amid R&D Focus

Odyssey Health, a medical product developer, faces significant going concern doubts and funding challenges despite progress in product development and a new sub-licensing agreement.

Summary

• Odyssey Health, Inc. is a development-stage company focused on acquiring and developing medical products, with two technologies in research and development: CardioMap (heart monitoring) and Save-A-Life (choking rescue device).
• No products have received regulatory clearance or approval for commercial sale, and the company has not generated any revenue since its inception.
• The CardioMap development program is suspended in the near term due to funding constraints, with the Save-A-Life device prioritized for further development.
• The company reported a net loss attributable to common stockholders of $(1,742,691) for the fiscal year ended July 31, 2025, an increase from $(905,771) in 2024.
• As of July 31, 2025, the accumulated deficit reached $62,745,837, with current liabilities of $7,004,421 and current assets of $49,723, resulting in a working capital deficit of $6,954,698.
• Cash on hand ($19,084 as of July 31, 2025) is not sufficient to support operations through the balance of the current calendar year, raising substantial doubt about the company's ability to continue as a going concern.
• In a subsequent event, the company entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc. for exclusive, worldwide rights to BreastCheck, a non-invasive test for breast abnormalities.
• General and administrative expenses decreased by 51% to $1,020,753 in fiscal 2025 from $2,084,446 in fiscal 2024.
• In fiscal 2024, the company sold drug candidates for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC) to Oragenics, Inc. for $1,000,000 in cash and 8,000,000 shares of convertible Series F preferred stock, resulting in a gain of $16,400,687.
• The company recorded an impairment of investment in preferred stock of Oragenics, Inc. of $12,955,437 in fiscal 2024 and a loss from change in fair value of Oragenics, Inc. common stock of $(459,417) in fiscal 2025.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position with significant losses, a large accumulated deficit, and insufficient cash to continue operations, leading to a going concern warning from its auditor. While there are some positive developments in product acquisition and cost reduction, the fundamental going concern issue and reliance on future highly dilutive capital raises for survival overshadow these. The suspension of a key R&D program (CardioMap) due to funding further highlights the severe challenges.

Positives

• Successfully sold drug candidates to Oragenics, Inc. in December 2023 for $1 million cash and preferred stock, generating a significant gain of $16,400,687.
• Secured exclusive, worldwide sub-licensing rights to BreastCheck, a non-invasive breast abnormality test, through an agreement with NeuRX Health, Inc. (subsequent event).
• Reduced general and administrative expenses by 51% ($1,063,693 decrease) in fiscal 2025 compared to fiscal 2024.
• Received a research and development rebate from the Australian government of $53,578 in fiscal 2024.

Negatives

• Net loss attributable to common stockholders increased by 92% to $(1,742,691) in fiscal 2025 from $(905,771) in fiscal 2024.
• Accumulated deficit grew to $62,745,837 as of July 31, 2025.
• Significant working capital deficit of $6,954,698 as of July 31, 2025.
• Cash on hand ($19,084) is insufficient to support operations through the balance of the current calendar year.
• The independent registered public accounting firm included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• Management concluded that internal controls and procedures were not effective as of July 31, 2025, due to insufficient resources and inadequate segregation of duties.
• The CardioMap development program is suspended in the near term due to funding constraints.
• No products have received regulatory clearance or approval for commercial sale, and no revenue has been generated since inception.
• Recorded an impairment of investment in preferred stock of Oragenics, Inc. of $12,955,437 in fiscal 2024.
• Incurred a loss from change in fair value of Oragenics, Inc. common stock of $(459,417) in fiscal 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and a significant accumulated deficit.
• The company needs to raise additional funds through equity or debt financing, which may not be available on acceptable terms and could lead to significant dilution for existing stockholders.
• A limited operating history and lack of revenue make it difficult for investors to evaluate prospects for success and assure profitability.
• The company expects to incur significant ongoing costs for infrastructure, growth, and regulatory compliance, which could materially impact financial results.
• There is uncertainty regarding the commercial feasibility and market acceptance of the CardioMap and Save-A-Life product candidates.
• Failure to obtain marketing authorization (FDA clearance or approval) for product candidates would materially and adversely affect the business.
• The company faces significant competition from larger, more established companies in the EKG equipment and anti-choking device markets.
• Reliance on third parties for worldwide marketing, distribution, and manufacturing of product candidates exposes the company to risks of delays, higher costs, or lost revenues.
• Competitors may develop new or improved products that are more convenient, effective, or less expensive, potentially displacing the company's products.
• The company is significantly dependent on outside scientists and third-party research institutions for its research and development efforts.
• Inability to adequately protect proprietary and intellectual property rights could lead to competitors gaining access to technology or costly litigation.
• The company faces an inherent risk of expensive product liability claims, especially as products enter clinical testing or commercialization, and currently carries no product liability insurance.
• Inability to effectively manage growth and expansion could harm the business if successful in acquiring and developing medical products.
• The company's business and operations could suffer from computer system failures, cyber-attacks, or deficiencies in cybersecurity.
• The common stock is deemed a 'penny stock,' which may make it more difficult for investors to sell shares due to suitability requirements.
• A limited public trading market for the common stock makes it difficult for stockholders to sell their shares.
• The company is heavily dependent on its small management team, and the loss of key personnel could materially adversely affect the business.
• Part-time consultants may have conflicts of interest due to other business endeavors.
• The company participates in transactions and makes tax calculations for which the ultimate tax determination may be uncertain, and its ability to use net operating losses may be limited.
• Failure to develop or maintain an effective system of internal controls could lead to inaccurate financial reporting or fraud, and management has already identified material weaknesses.

Future Outlook

The company intends to acquire other technologies and assets, aiming to be a trans-disciplinary product development company involved in the discovery, development, and commercialization of products across various medical markets. Plans include licensing, improving, and developing products, identifying distribution channels, and engaging third-party research and development firms. International growth is a focus, with an objective to generate revenue through marketing and sales of product candidates like CardioMap and Save-A-Life, once regulatory approvals are secured. Future growth is anticipated from distribution or license agreements, developing products for additional proprietary uses (e.g., CardioMap for brain, liver, kidney), and the development and acquisition of new products. The company also intends to seek partners for further development and clinical trials of its drug device combination products.

Management Comments

• "Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have superior clinical utility and serve an unmet medical need."
• "Our business model is to develop or acquire medical-related products, engage third parties to help develop, complete clinical trials and manufacture products according to FDA regulations."
• "Due to funding constraints and market conditions, the Save-A-Life will be prioritized for further development. The CardioMap development program will remain suspended in the near term."
• "Although no assurances can be given, management anticipates company growth from the following areas: 1) Distribution or License Agreements. 2) Identify and develop our products for additional proprietary uses. 3) The development and acquisition of new products. 4) Seek partners to assist in the further development of our drug device combination products."
• "We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan."

Industry Context

Odyssey Health operates within the highly regulated and competitive medical device and pharmaceutical research and development sectors. The company's focus on preventative medicine, particularly with devices like CardioMap for early heart disease detection and BreastCheck for breast abnormalities, aligns with broader healthcare trends emphasizing early diagnosis and cost reduction. The choking rescue device, Save-A-Life, addresses an emergency medical need. The industry is characterized by rapid technological change, significant capital requirements for R&D and regulatory approval, and intense competition from larger, more established players. The company's strategy of relying on third parties for development, manufacturing, and distribution is common for development-stage companies but also exposes it to specific industry-related risks.

Comparison to Industry Standards

• CardioMap is intended to offer improved sensitivity for early coronary heart disease (CHD) detection and 3-D visualization, potentially providing a better level of diagnosis compared to standard EKG devices such as CardioResting (Nasiff), Welch Allyn PC Based Electrocardiograph, and wireless systems like QardioCore.
• The Save-A-Life choking rescue device is designed to be a safe, easy-to-use, and instantly effective solution, competing with existing devices like Dechoker and LifeVac, which also utilize suction, and the Act+Fast Heimlich maneuver training vests.
• The company's reliance on third-party contract manufacturing and distribution partners is a common operational model in the medical device and pharmaceutical industries for companies lacking internal infrastructure, but it introduces risks related to supply chain, quality control, and regulatory compliance.

Corporate Governance

Legal Proceedings

• As of the date of this filing, the company is currently not a party to any legal proceedings.

Related Party Transactions

• Amounts due to Joseph M. Redmond, CEO, for reimbursement of expenses totaled $17,125 as of July 31, 2025.
• Amounts due to Christine M. Farrell, CFO, for reimbursement of expenses totaled $34,085 as of July 31, 2025.
• Unpaid salary and bonus due to Joseph M. Redmond, CEO, totaled $1,330,308 as of July 31, 2025.
• Unpaid salary and bonus due to Christine M. Farrell, CFO, totaled $476,925 as of July 31, 2025.
• Promissory notes issued to officers and directors totaled $100,000 as of July 31, 2025, bearing 8.0% interest per annum and convertible at $0.12 per share.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity raises, potential loss of their entire investment due to the company's going concern issues, and challenges in liquidity due to the limited public trading market and 'penny stock' status.
• Employees (currently two) are subject to the high risk of business failure, and there are no plans to hire additional employees in the foreseeable future.
• Customers are not yet directly impacted as no products are commercially available, but future success depends on regulatory approvals and market acceptance of products like CardioMap, Save-A-Life, and BreastCheck.
• Creditors face elevated risk due to the company's substantial doubt about its ability to continue as a going concern and its reliance on future financing to meet its obligations.
• Management, particularly the CEO and CFO, have significant accrued salaries and bonuses, indicating deferred compensation and a vested interest in the company's future success, but also face the challenges of securing funding and navigating regulatory hurdles.

Next Steps

• Obtain regulatory clearance or approval (FDA) for CardioMap and Save-A-Life product candidates.
• Secure additional funding through debt or equity financing to meet short and long-term operating requirements and execute the business plan.
• Enter into distribution or license agreements for commercialized products, both domestically and internationally.
• Prioritize and further develop the Save-A-Life choking rescue device.
• Seek partners to assist with the further development and clinical trials of drug device combination products.
• Pursue development of CardioMap technology for additional proprietary uses in other areas of the human body (e.g., brain, liver, kidney) when funding allows.
• Identify and acquire new product candidates and technologies.
• Implement improvements to internal controls to address identified material weaknesses, potentially by using third-party specialists and increasing independent reconciliations.
• Finalize certain terms and closing conditions for the Master Technology and Sub-license Agreement with NeuRX Health, Inc. for BreastCheck.

Key Dates

Recommendation

Odyssey Health, Inc. is in a critical financial state, marked by a substantial accumulated deficit, negative working capital, and insufficient cash to sustain operations beyond the current calendar year. The independent auditor's explicit 'going concern' warning, coupled with management's acknowledgment of ineffective internal controls, signals severe operational and financial instability. While the company has some promising product candidates and a new sub-licensing agreement, the suspension of a key R&D program (CardioMap) due to funding constraints underscores its precarious position. The heavy reliance on highly dilutive equity and convertible debt financing, along with the stock's 'penny stock' status and illiquid market, presents an exceptionally high risk profile. Given these fundamental weaknesses and the high probability of further value erosion, a 'strong sell' recommendation is warranted.

Keywords

Medical devices, Healthcare, R&D, CardioMap, Save-A-Life, Choking rescue device, Heart monitoring, FDA approval, SEC filing, 10-K, Development stage, Going concern, Capital raise, Intellectual property, Biotechnology, NeuRX Health, BreastCheck, Financial reporting, Corporate governance